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Case History
Amiodarone-Induced Hyperthyroidism in a Patient 
with Functioning Papillary Carcinoma of the 
Thyroid and Extensive Hepatic Metastases
Gavin C. Mackie and Barry L. Shulkin
Thyroid hormone producing thyroid carcinoma is an uncommon cause of thyrotoxicosis. A patient with ex-
tensive hepatic metastases from well-differentiated carcinoma is presented. Administration of amiodarone for
atrial fibrillation led to the development of hyperthyroidism. Precipitation of thyrotoxicosis by iodine-containing
compounds in patients with thyroid carcinoma is rare. The relatively high iodine load and the slow elimina-
tion of amiodarone complicate the clinical management of such patients.
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Introduction
THYROTOXICOSIS IN PATIENTS with thyroid cancer is un-common. It may be the result of a variety of causes, es-
pecially excess thyroid hormone intake. Occasionally, well-
differentiated thyroid carcinoma may produce thyroid
hormone in response to a variety of stimuli, including an-
tithyroidal antibodies or iodine. We describe a patient with
extensive hepatic metastases who became thyrotoxic while
receiving amiodarone therapy for atrial fibrillation.
Case Report
A 77-year-old man with a history of valvular and athero-
sclerotic heart disease presented with a right-sided thyroid
mass for which he underwent a right thyroid lobectomy and
partial left thyroid lobectomy. Histopathology revealed well-
differentiated papillary cancer with follicular elements. The
tumor was 6 cm in maximum dimension. There was capsu-
lar invasion but no evidence of nodal or other extrathyroidal
involvement or distant spread. The MACIS (metastasis, age,
completeness of resection, invasion, and size) score was 8.56
(1). Approximately 6 weeks postthyroidectomy, the patient
underwent ablation of the thyroid remnant with 30 mCi of
radioactive iodine (131I). Posttherapy images showed uptake
in the thyroid bed, more prominent on the left than the right.
Follow-up 131I scanning 3 months later showed residual ra-
dioactive iodine uptake in the neck and right upper quad-
rant of the abdomen. He was treated with 175 mCi of 131I.
Four months later, a left-sided neck mass was discovered.
The patient underwent resection of residual thyroid tissue
and dissection of left jugular lymph nodes. Histopathology
demonstrated postoperative and postradiation changes but
no residual neoplasia. However, the thyroglobulin level was
elevated at 420 ng/mL (normal,  60 ng/mL). A whole-body
131I scan 6 weeks postoperatively again demonstrated ab-
normal uptake in the neck and right upper quadrant of the
abdomen. The patient received an additional 175 mCi 131I for
the residual uptake.
During the subsequent 3 years, the patient received 150
g thyroxine daily. Two 131I whole-body scans were re-
ported to show no abnormal uptake in that period. The thy-
roglobulin rose to 2100 ng/mL. He was then referred to the
University of Michigan. 131I scintigraphy showed irregular
mottled liver uptake suspicious for liver metastases (Fig. 1).
Ultrasound-guided needle biopsy showed well-differenti-
ated thyroid carcinoma within the liver. The patient was
treated with 250 mCi 131I. Two months later the thyroglob-
ulin level was stable, measuring 2110 ng/mL with the pa-
tient taking 150 g thyroxine. He remained relatively asymp-
tomatic for the next 18 months, treated cautiously with 175
g thyroxine to suppress thyrotropin (TSH) to barely de-
tectable levels without aggravating his known coronary and
valvular heart disease. The thyroglobulin level rose to 47,200
ng/mL. CT scan showed numerous hypervascular masses in
the liver (Fig. 2). An FDG PET scan demonstrated increased
uptake within the hepatic lesions. He remained asympto-
matic from thyroid carcinoma. Two years later, the thy-
roglobulin rose further to 64,200 ng/ml while the patient was
taking 175 mcg thyroxine daily. During a hospitalization
elsewhere computed tomography (CT) scanning again
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showed multiple hepatic metastases and a new lesion ini-
tially thought to arise from the pancreas. Biopsy of this mass
was initially interpreted as follicular carcinoma and later re-
vised to well-differentiated thyroid carcinoma. The patient
returned to the University of Michigan for follow-up of thy-
roid cancer.
The patient appeared cachetic but had no specific com-
plaints. His weight had decreased from 164 to 127 pounds
over the preceding 12 months. Medications included thy-
roxine, which had been decreased to 50 g per day. Pulse
rate was 88 beats per minute. There was a prominent sys-
tolic ejection murmur radiating to the carotid arteries. The
liver was enlarged, measuring approximately 15 cm in length
in the midclavicular line. There was marked lower extrem-
ity edema. At this point it was unclear whether his deterio-
rating status was the result of congestive heart failure, pro-
gressive tumor burden, or another etiology. A fluorine-18
2-fluoro-2-D-glucose–positron emission tomography (FDG-
PET) scan was obtained to evaluate the extent of thyroid car-
cinoma and to search for other malignancies. FDG-PET scan-
ning showed multiple areas of abnormal activity within the
liver and an irregular, focal concentration in the right ab-
domen (Fig. 3), corresponding to the previously described
mass. CT also showed multiple small pulmonary nodules
consistent with metastases.
Because of his comorbidities, Thyrogen-stimulated thy-
roid cancer scanning was performed to determine whether
the new mass concentrated radioiodine and could be treated
with 131I. 123I scintigraphy after human thyrotropin (hTSH)
stimulation showed no focal abnormal areas of uptake
within the liver or within other sites of known thyroid can-
cer metastases (Fig. 4). At this time the free thyroxine (T4)
had risen to 3.56 ng/dL (normal, 0.73–1.79 ng/dL). TSH re-
mained suppressed ( 0.01 U/mL). The patient and his
daughter denied thyroid hormone ingestion other than the
prescribed 0.50 mg daily, and the possibility of autoimmune
induced hyperfunction of thyroid metastases was raised.
Thyroid-stimulating immunoglobulins (TSI) were less than
1 (negative if  1.3). Careful review of the patient’s medica-
tion with his daughter showed that he had had amiodarone
prescribed several months previously for an episode of atrial
fibrillation; the amiodarone had been stopped 3 weeks prior
to evaluation. Thyroid hormone was stopped and the patient
was treated with methimazole. One week later the free T4
declined to 2.99 ng/dL. The hyperthyroidism was thus at-
tributed to endogenous thyroid hormone production by the
well-differentiated hepatic metastases in response to the io-
dine load from amiodarone. The patient was referred for che-
motherapy but declined. Four-month follow-up showed that
the patient had gained 6 pounds and his thyroid hormone
had been restarted at 0.1 mg daily. The patient’s free T4 level
fell to be below normal limits (0.4 ng/dL) despite the pres-
ence of progressive metastatic disease. The patient died
about 6 months later from congestive heart failure. Labora-
tory values and the clinical course are summarized in Table
1 and Figure 5.
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FIG. 1. Radioactive iodine (131I) whole-body scintigraphy 24 hours after
administration of 1 mCi 131I demonstrating irregular, intense activity in the
liver consistent with hepatic metastases.
FIG. 2. An axial contrast-enhanced computed tomography (CT) showing
multiple hypervascular, enhancing lesions throughout the liver consistent
with hepatic metastases. Several of these lesions show central areas of re-
duced density consistent with necrosis.
FIG. 3. Anterior projection image from fluorine-18 2-fluoro-2-D-glu-
cose–positron emission tomography (FDG-PET) scan demonstrating multi-
ple areas of abnormal metabolic activity in the liver consistent with metas-
tases. Note also the abnormal activity in the mid-right abdomen (arrow).
FIG. 4. 123I whole-body scintigraphy with 5 mCi 123I performed about 3
weeks after cessation of amiodarone showed no radioactive iodine concen-
trating metastatic disease. Lack of uptake was attributed to amiodarone-re-
lated iodine overload.
Discussion
Thyroid carcinoma rarely produces clinically substantial
amounts of thyroid hormone, and thyrotoxicosis due to func-
tioning thyroid carcinoma metastases is uncommon. In a re-
view of the literature in 1990, Paul and Sisson (2) found only
48 cases of hyperthyroidism associated with well-differenti-
ated thyroid carcinoma. In most cases in which thyroid car-
cinoma and thyrotoxicosis coexist, thyrotoxicosis is usually
caused by Grave’s disease with the thyroid carcinoma being
an incidental finding (3). In the patient described, there was
no detectable radioiodine uptake by the thyroid metastases
at the time the patient was hyperthyroid, although iodine-
avid metastases in the liver had been previously docu-
mented. The absence of radioactive iodine uptake was due
to the high iodine load from amiodarone. Thus the hepatic
metastases were almost certainly the source of the excess T4
given the absence of residual normal thyroid tissue after sur-
gery and multiple 131I therapies.
Thyrotoxicosis in patients with metastatic thyroid carci-
noma usually results from a large bulk of tumor functioning
either autonomously, or in a patient with coexisting Grave’s
disease caused by stimulation of TSH receptors on the met-
astatic cells by TSI (4,5). The latter mechanism may occur in
more than half of cases with functioning metastases (2). We
were able to identify only one other reported case in which
excess iodine was a precipitating factor; in that patient the
excess iodine was due to iodinated radiographic contrast (6).
Exposure to increased quantities of iodine may induce hy-
perthyroidism in a patient who was previously euthyroid
(Jod-Basedow phenomenon). This usually occurs in areas of
endemic iodine deficiency, mainly in patients with nontoxic
multinodular goiter. It may be associated with low radioio-
dine uptakes (7). Iodine-associated thyrotoxicosis in func-
tioning thyroid metastases is a potentially fatal complication
in patients with thyroid carcinoma who may have an abrupt
increase in circulating thyroid hormone levels after ingestion
of iodine-containing medications (6).
The treatment of amiodarone-induced hyperthyroidism
includes the cessation of amiodarone if possible. Because of
tissue storage of the amiodarone and its metabolites, and its
slow release, thyrotoxicosis may persist for several months
after cessation of the drug (8). Methimazole with potassium
perchlorate has been advocated as the treatment of choice
for most patients with amiodarone-induced thyrotoxicosis,
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TABLE 1. SUMMARY OF THE THYROXINE DOSE, THYROGLOBULIN, THYROID-STIMULATING HORMONE, 
AND FREE THYROXINE LEVELS OVER THE COURSE OF THE PATIENT’S TREATMENT
Date/ Thyroxine Tg TSH FT4 Weight
diagnosis dose (g) (ng/mL) (mlu/L) (ng/dL) (lbs) Comment
1 month 0 200 2.4 0.7 Right lobectomy and partial left lobectomy
5 months 125 420 16.2 0.5 Microsomal and thyroglobulin antibodies absent;
30 mCi 131I
9 months 125 120 4.1 1.6 5 mCi 131I scan: large focus uptake left thyroid lobe;
treatment with 175 mCi 131I
1 year 125 420 Tg antibodies absent
2 years 125 1100 0 1.9 5 mCi 131I scan: uptake right neck and RUQ; Left
lobectomy followed by 175 mCi 131I
4 years 150 5 mCi 131I scan: no uptake in neck
5 years 150 2100 0.12 1.4 201 3 mCi 131I scan: no uptake in neck
6 years 175 2080 0.01 1.65 199 4 mCi 131I scan: liver metastases; treated with 250 mCi 131I
7 years 125 47200 0.01 0.76 171 Clinically doing well
8 years 125 38100 0.01 0.05 164 Clinically doing well
8 years, 125 CT and PET scanning showed liver and lung metastases
10 months Amiodarone begun for supraventricular tachycardia
9 years, 0 64200  0.01 2.99 127 Amiodarone stopped; 5 mCi 123I scan: no uptake in
4 months liver or other metastases
9 years, 100 133 Died 6 weeks later from complications of metastases
8 months
T4, thyroxine; Thyroxine dose  Prescribed daily dose of thyroxine (g); TG  thyroglobulin (ng/mL); TSH  thyroid stimulating 
hormone (normal 0.3–5.5 mlu/L); FT4,  free thyroxine (normal 0.73–1.79 ng/dL); CT, computed tomography; PET, positron emission 
tomography
FIG. 5. Graphical description of thyroglobulin and free thy-
roxine (T4) values over the clinical course with reference to
prescribed T4 doses.
and -adrenergic antagonists may also be useful unless con-
traindicated. In patients with functioning thyroid carcinoma
metastases, antithyroid drugs given alone may be useful in
providing temporary control of the thyrotoxicosis, but ide-
ally therapy should allow simultaneous treatment of the un-
derlying malignancy and the thyrotoxicosis (3,9).
131I has the potential to result in both improvement in the
thyrotoxicosis and reduction of the thyroid carcinoma tumor
bulk (10,11). Treatment of functioning thyroid carcinoma
metastases with radioiodine requires consideration of sev-
eral specific issues. Firstly, usual thyroid cancer therapy
doses of 131I may be deleterious if administered to patients
with functioning metastases. Patients with functioning bulky
metastases may secrete high amounts of radiothyroxine. This
persists in the circulation with a half-life of 3–4 days, result-
ing in higher than usual radiation of normal tissues. Stan-
dard dosing of radioiodine assumes a low radioiodine up-
take (often less than 1% of administered activity) by
metastatic tissue. This is often not the case in patients with
functioning tumor, which often accumulates considerably
more 131I (11). Although significant acute toxicity and bone
marrow suppression are very uncommon after “routine” ra-
dioiodine therapy, patients with a large tumor burden and
elevated serum T4 levels are at higher risk for toxicity, with
the potential for development of bone marrow suppression
and radiation pneumonitis. Because of the prolonged reten-
tion of 131I, dosimetry is recommended. (11). Body retention
of 131I should be measured and it has been suggested that if
the patient is hyperthyroid, the maximum permissible dose
should be reduced to 50%, because of the formation of cir-
culating radiothyroxine, which has a longer biological half-
life than radioiodine. When determining the therapy, care-
ful consideration also needs to be paid to the general health
of the patient, the extent of the tumor and the patient’s tol-
erance of hyperthyroxinemia (12).
131I therapy in patients with well-differentiated thyroid
carcinoma producing thyroid hormone could exacerbate thy-
rotoxicosis, leading to thyroid storm and death. Because of
this potential risk, some have recommended that the patient
should be rendered euthyroid with antithyroid drugs if pos-
sible prior to radioiodine therapy (13). Pretreatment with an-
tithyroid drugs likely lowers the risk of a thyroid storm by
depleting the stored thyroid hormone within the metastatic
disease.
In conclusion, amiodarone induced hyperthyroidism can
occur not only in patients without previously known thyroid
disease, but also in the uncommon patient with well differ-
entiated metastatic thyroid cancer. Careful monitoring of
such patients for thyrotoxicosis is in order if iodine contain-
ing medications are considered essential.
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